Skip to main content

Table 2 Main reported psoriasis-associated HDL alterations

From: Psoriasis-associated vascular disease: the role of HDL

Ref: number of subjects

HDL alterations

Mehta (42): 112 patients

Reduced cholesterol efflux capacity

Holzer (35): 15 patients

Reduced cholesterol efflux capacity

Reduced apoA-I, apoA-II, apoM

Reduced phospholipid (phosphatidylcholine and sphingomyeline) and cholesterol content

Increased SAA, prothrombin, α-1-anti-trypsine, α-1-acid-glycoprotein 1

Not altered PON-1 activity

Holzer (51): 15 patients

Reduced cholesterol efflux capacity

Reduced apoA-I and apoM

Reduced phospholipid (phosphatidylcholine and sphingomyeline) and cholesterol content

Increased SAA, prothrombin, α-1anti-trypsine, α-1-acid glycoprotein 1

Reduced PON-1 activity

He (44): 25 patients

Reduced PON-1 activity

Reduced anti-inflammatory activity

Usta (45): 25 patients

Reduced PON-1 activity

Ferretti (46): 23 patients

Reduced PON-1 activity

Increased lipid peroxidation

Toker (20): 30 patients

Increased PON-1 activity

Tom (43): 44 paediatric patients

Reduced cholesterol efflux capacity

  1. HDL high-density lipoprotein, apoA-I apolipoprotein A-I, apo-A-II apolipoprotein A-II, apoM apolipoprotein M, SAA serum amyloid A, PON-1 paraoxonase 1